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Abstract In traditional chinese medicine several Aristolochia
species are used. Aristolochia spp. contain a mixture of
aristolochic acids (AAs), mainly AA I and AA II which are
nephrotoxicants and carcinogens. After AA-related nephrop-
athy (AAN) and urothelial cancer were described in female
patients in Belgium following intake of AA-contaminated
herbal preparations, herbs with AAs were prohibited
worldwide. Confusing nomenclature can cause AA contam-
ination of certain Chinese traditional herbal preparations
(THPs). Here we report the results of investigations by the
Dutch Food and Consumer Product Safety Authority (VWA)
into the presence of AAs in THPs sampled on the Dutch
market using a liquid-chromatography–-mass spectrometry
method. Between 2002 and 2006 we sampled 190 Chinese
THPs using recent information on Chinese THPs potentially
containing AAs. AA I was found in 25 samples up to a
concentration of 1,676 mg/kg. AA II was also found in 13 of
these samples up to 444 mg/kg. All 25 positive samples
including Mu Tong, Fang Ji, Tian Xian Teng and Xi Xin
were part of a group of 68 THPs identified as possibly
containing AAs. In a worst-case scenario, use of a sample of
Mu Tong with the highest AA content over a 7-day period
would result in the same intake levels of AAs which
significantly raised the cancer risk in the Belgian AAN
cases. Our results show that contaminated THPs still can be
found on the market following worldwide publicity. There-
fore, it can be concluded that testing of possibly AA-
contaminated THPs is still essential.
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Abbreviations
AA Aristolochic acid
AAN Aristolochic acid nephropathy
BEN Balkan endemic nephropathy
CHN Chinese herb nephropathy
CYP Cytochrome P450
LC Liquid chromatography
LOD Limit of detection
LOQ Limit of quantification
MS Mass spectrometry
QC Quality control
SCM Standardized control material
TCM Traditional chinese medicine
THP Traditional herbal preparation
VWA Dutch Food and Consumer Product Safety
Authority
Introduction
In traditional chinese medicine (TCM) Aristolochia species
such as A. fangchi and A. manshuriensis and others are
used to treat snake and insect bites, promote lactation or
urination and reduce edema [1]. Aristolochia spp. are used
for medicinal purposes worldwide. Many herbs from the
genus Aristolochia and several species of the genus
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Asarum, both belonging to the family of the Aristolocha-
ceae, contain several aristolochic acids (AAs) often accom-
panied by aristolactams [2–4]. Literature on the toxicity of
the Aristolochiaceae and related analytical papers mostly
focus on a naturally occurring mixture of AAs mainly
consisting of AA I and AA II (Fig. 1) [5].
AAs were shown to be nephrotoxic and carcinogenic in
animal studies with rodents [5, 6]. It has been shown in rat
studies that the renal proximal tubule is an important target
of AA toxicity which can result in renal failure [7, 8]. AAs
have been suggested to play a role in the Balkan endemic
nephropathy (BEN) characterized by renal interstitial
fibrosis. Seeds of A. clematitis, which is ubiquitous in
BEN-affected areas, may have contaminated grain [9]. The
International Agency for Research on Cancer concluded
that herbal preparations with Aristolochia spp. are carcino-
genic to humans and that naturally occurring mixtures of
AAs are probably human carcinogens as well [10]. In
humans the hepatic and renal activation of AAs is attributed
to reductive metabolic activation by cytochrome P450
(CYP) 1A1, CYP1A2, NAD(P)H:quinone oxidoreductase
and others. The resulting ultimate carcinogenic species is
able to form adducts with DNA, which in turn can cause
mutations and neoplastic changes [5, 11]. We recently
reviewed the toxic action of AA in some detail [12].
TCM is gaining popularity in Western countries but
certain safety issues of Chinese traditional herbal prepara-
tions (THPs) such as the deliberate use of high amounts of
heavy metals [13] and the presence of AAs invariably
require attention. In the USA and the Netherlands Chinese
THPs are regarded as foods. In Dutch food law THPs are
regulated as herbal preparations in the Commodities Act
“Herbal preparations.” Since it came into force in early 2001,
this Act has prohibited the presence of AAs and their
derivatives in herbal preparations with Aristolochia spp.
This ban was recently extended to all herbal preparations
irrespective of the plant species present. Several other
countries, such as the UK, the USA, Canada, Australia and
New Zeeland, have since 2000 significantly limited or
prohibited the sale of AA-containing herbs and issued
warnings [14–18]. These measures were inspired by a
steadily expanding insight into the nature of the causative
agent of poisonings with Chinese THPs in Belgium in the
early 1990s. In 1992 a cluster of nine similar cases of renal
interstitial fibrosis in female patients was identified in
Brussels. All these patients were treated between 1990 and
1992 in a slimming clinic with a regimen consisting of a
diet, injections and capsules containing pharmaceuticals
such as fenfluramine, herbal preparations and a pancreas
extract. In early 1990 the clinic had altered the THP
formulation by introducing the Chinese herbs Magnolia
officinalis and Stephania tetrandra to the capsules, replac-
ing other herbs. It was suggested that S. tetrandra was
inadvertently replaced by A. fangchi. Thin-layer chroma-
tography detection of AAs in these herbal preparations
failed however [19]. Afterwards AAs were found in 11 of
the 12 batches of S. tetrandra powder delivered to Belgian
pharmacies during the treatment period [20]. The disease
became known as Chinese herb nephropathy (CHN). After
the initial report more than 100 cases of rapidly progressing
renal fibrosis associated with exposure to AAs were
identified in Belgium and approximately 170 cases of AA-
associated CHN were described in other European countries,
the USA and in Asia [5]. In renal tissue of 39 patients who
were treated with the Belgian slimming regimen and who
were followed for CHN-related end-stage renal failure 18
cases of urothelial cancer were identified. All tissue samples
examined contained AA-related DNA adducts [21]. It was
found that a total intake of more than 200 g S. tetrandra
(probably mostly replaced by A. fangchi) was associated
with a higher risk of urothelial carcinoma [21]. A statistical
analysis of the prescriptions and medical files of 71 CHN
patients showed that of all administered drugs only the
cumulative dose of the contaminated S. tetrandra prepara-
tion could predict the renal failure progression rate [22].
The typical chronic interstitial lesions of CHN were
reproduced in rats injected with 10 mg/kg/day of a mixture
of 40% AA I and 60% AA II for 35 days [7]. Nowadays
many authors prefer to use the more accurate term
“aristolochic acid nephropathy” (AAN) over the term CHN.
As a result of the Belgian CHN cases it became better
known why certain Chinese THPs are contaminated with
AAs and what the effects of exposure to AAs can amount
to. Confusion over the Chinese common name “Fang Ji,”
which can refer both to the roots of S. tetrandra and A.
fangchi, could have caused the contamination with AAs
[19, 20]. In the trade of Chinese herbs the substitution of
one plant species for another is established practice [23].
Besides the THPs known to contain Aristolochia species
some THPs derived from certain plant species can be
identified which can be replaced by Aristolochia species in
practice. Several international food and medicine authori-
ties have published lists of THPs suspected to contain AA.
The Dutch Food and Consumer Product Safety Authority
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Fig. 1 Structure of aristolochic
acid I (R is OCH3) and aristo-
lochic acid II (R is H)
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(VWA) has implemented these lists in its sampling
strategies of Chinese THPs and analyzed AAs in commer-
cial samples. Reports providing quantitative data on AA
levels of commercial THPs possibly containing AAs are
scarce. Such data could, however, be useful to validate the
existing lists of suspected THPs and could help authorities
to pinpoint their efforts to protect the consumer against
exposure to AAs. In the present paper our results in this
field over the past 4 years are presented and compared with
recent scientific and regulatory data.
Materials and methods
Sampling
VWA inspectors sampled 190 Chinese THPs on the Dutch
market in the period from November 2002 to June 2006.
Samples were selected by using a list of single-herb THPs
and multi-ingredient THPs probably and possibly contain-
ing AAs which was based on a list compiled by the FDA in
2001 [24]. The FDA list was supplemented and regularly
updated in-house with data on the nomenclature of AA-
containing herbal material from books on TCM, commer-
cial TCM databases on the Internet, warnings of other
inspection agencies and literature [1, 15, 23–28, 38, 40, 42].
Table 1 presents an extract of our sampling list defining the
most pertinent Aristolochia species in use in TCM and
several plant species with which they could be exchanged.
The Chinese common names in the table refer to plants and
the parts used and are given in Pin Yin, which is a phonetic
representation of Chinese characters. The corresponding
Latin pharmaceutical name also presented is a combination
of the part of the plant and often its binomial botanical
name. Both types of nomenclature are seen in the market.
Table 2 presents examples of formulas which can be
potentially contaminated with AAs through the presence
of Mu Tong, Fang Ji or Xi Xin. For sampling, products
were selected by formula name or by screening the
ingredient list for suspected herbs. Along with THPs known
or suspected to contain AAs, THPs were sampled at
random as well. THP names were copied as labeled and
are presented in this paper without alterations. Generally no
authentication of the herb was performed.
THPs were collected in TCM stores, oriental food stores,
wholesale dealers, importers or TCM practitioners through-
out the Netherlands. Sampling inspections were held at
least each year. Locations were selected from the VWA-
inspection database. During inspections of these locations,
new suppliers and stores were also identified and visited.
THPs were sampled in prepackaged form in capsules or
tablets or in many cases in the form of coarse herbal
material from glass containers sometimes with limited or no
labeling. Samples were taken on the basis of quantities
supplied to consumers, which is one unit (e.g., bottle,
package or container) or in case of coarse herbal material in
amounts higher than 10 g. Mixtures of the coarse materials
are assembled in TCM shops according to a formula
prescribed by an in-house TCM practitioner. This THP
mixture is then prepared at home as a decoction for which
Table 1 Examples of single-herb traditional herbal preparations (THPs) possibly containing aristolochic acids
Pin Yin name Part used Botanical name Latin pharmaceutical name, including alternative names
THPs with Aristolochia species
Guang Fang Ji Root Aristolochia fangchi Radix Aristolochia fangchi/Aristolochiae Fangchi
Ma Dou Ling Fruit A. contorta and A. debilis Fructus Aristolochiae
Tian Xian Teng Herb A. contorta and A. debilis Herba Aristolochiae/Caulis Aristolochiae
Guan Mu Tong Stem A. manshuriensis Caulis Aristolochia manshuriensis/Aristolochiae
Manshuriensis
Qing Mu Xiang Root A. debilis Radix Aristolochiae
Xun Gu Feng, Bai Mao
Teng
Herb A. mollissima Herba Aristolochiae Mollissimae
THPs possibly contaminated with Aristolochia species
Han Fang Ji Root Stephania tetrandra Radix Stephania tetrandra
Mu Fang Ji Root Cocculus trilobus and C. orbiculatus Radix Cocculi Trilobi/Radix Cocculus trilobus/Radix Cocculi
Chuan Mu Tong Stem Clematis armandii Caulis Clematis armandii/Clematidis armandii
Chuan Mu Tong Stem Clematis montana Caulis Clematidis/Clematis montana/Clematis armandii
Bai Mu Tong Stem Akebia quinata Caulis Akebia quinata
Bai Mu Tong Stem Akebia trifoliata Caulis Akebia trifoliata
Bai Mao Teng, Bai Ying Herb Solanum lyratum Herba Solani Lyrati
From [1, 23, 24, 27, 42]
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the herbs are boiled in water or other liquids. The strained
liquid is then consumed [1].
Experimental
The method used to quantify AA I and AA II was based on
the method described by Flurer et al. [29]. The entire
sample was homogenized or in the case of capsules the
contents of all the capsules were taken and homogenized,
and from this a laboratory sample was taken for further
analysis. After homogenization 25 ml of extraction solution
was added to 1 g of sample. The extraction solution existed
of 80% methanol, 18% water and 2% formic acid. The
samples were shaken for 90 min in a shaking machine
(Gerhardt LS-20, position 9). Then they were allowed to
precipitate for about 1 h. An aliquot of 1 ml was then
centrifuged at a minimum of 10,000g. The supernatant was
transferred to a vial and hermetically sealed for liquid
chromatography (LC)–mass spectrometry (MS) analysis.
No concentration step was needed.
An ion-trap LC-MS system from Thermofinnigan (LCQ
Advantage) equipped with a quaternary pump, an autosam-
pler with a column oven, a photodiode array detector and
an integration system together with LC-MS software was
used for analysis. The separation was performed on an
Alltima C-18 column (150 mm×3.2-mm inner diameter—
5-μm particle size) with an Alltima C-18 precolumn
(7.5 mm×3.0-mm inner diameter—5-μm particle size)
using gradient elution. LC conditions are listed in Table 3.
The MS detection was performed by electrospray ionization
using the positive mode. The MS conditions are listed in
Table 2 Examples of multi-ingredient THPs possibly containing AAs
Formula name in Pin Yin, in alphabetical order
Formulas with Mu Tong or Fang Ji
Anyang Jingzhi Gao Fang Ji Huang Qi Tang Quell Fire
Ba Zheng Wan Fenqing Wulin Wan Shang Zhong Xia Tong Yong Tong Feng Fang
Chi Kuan Yen Wan Fu Ke Fen Qing Wan Shi Xiang Fan Shen Wan
Chu Shi Wei Ling Tang Gan Lu Xiao Du Dan Shu Feng Huo Xue Tang
Chun Yang Zheng Ji Wan Guan Xin Su He Wan Shu Jing Huo Xue Tang
Da Huang Qing Wei Wan Guo Qi Yin Tienchi Hugu Wan
Da Qiang Huo Tang Ji Jiao Li Huang Wan Xiao’er Jindan tablets
Dang Gui Si Ni Tang Ji Sheng Ju He Wan Xiao Feng San
Dang Gui Si Ni Wan Jia Wei Wu Lin San Xiao Huo Luo Dan
Dao Chi San Ju He Wan Xiao Xu Ming Tang
Dao Chi Wan Kat Kit Wan Xin Yi Wan
Dieda Wan Kuanhsin Suhowan Xuan Bi Tang
Er Jia Jian Zheng Qi San Long Dan Xie Gan Tang Zhisou Huatan Wan
Ershiwuwei Songshi Wan Long Dan Xie Gan Wan Zhu Ling Tang
Fang Ji Fu Ling Tang Mu Fang Ji Tang
Formulas with Xi Xin
Chuan Xiong Cha Tiao San Du Huo Ji Sheng Tang San Bi Tang
Chuan Xiong Cha Tiao Wan Jiu Wei Qiang Hou Tang She Gan Ma Huang Tang
Da Huang Fu Zi Tang Ling Gan Wu Wei Jiang Xin Tang Tong Guan San
Da Qin Jiao Tang Ma Huang Fu Zi Xi Xin Tang Wu Mei Wan
Dang Gui Si Ni Tang Qu Feng Zhi Bao Dan Xiao Qing Long Tang
From [15, 24, 25, 27, 38, 40, 42]
Table 3 Liquid chromatography (LC) conditions for the determination
of AA I and AA II
Parameters Conditions
Analytical column Alltima C-18 column (150 mm×3.2-mm inner
diameter—5-μm particle size)
Precolumn Alltima C-18 (7.5 mm×3.0-mm inner
diameter—5-μm particle size)
Column temperature 30°C
Injection volume 20 μl (full-loop injection)
Flow rate 0.30 ml/min
Mobile phase Eluent A: 10 mmol ammonium formate in
1% formic acid
Eluent B: Methanol
LC gradient Time (min) Eluent A (%) Eluent B (%)
0.00 50 50
10.00 20 80
21.00 20 80
22.00 0 100
25.00 0 100
26.00 50 50
34.00 50 50
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Table 4. Before injection of samples, the system was
equilibrated using 50% eluent A and 50% eluent B.
Quantification of AA I and AA II was based on a standard
mixture obtained from Sigma-Aldrich (Zwijndrecht, The
Netherlands) containing 43% AA I and 54% AA II.
For every series of samples several quality checks were
performed, including a check of the validity of calibration,
a check on the ratio of the first to the second daughter ion
and the analysis of quality control (QC) samples (two
standardized control materials, SCMs, containing AA I or
AA II). For this QC material the mean and a 95%
confidence interval were established. Each measurement of
this QC material had to comply with this 95% confidence
interval. AAwas only quantified when all quality checks for
a series of samples were in line with the desired performance
characteristics.
Results and discussion
Characteristics of the analytical method
For the in-house validation of the method for quantifying AA
I and AA II, the limit of detection (LOD) and the limit of
quantification (LOQ) were determined. The LODwas defined
as the concentration which is 3 times higher than the range of
the chromatographic background of the second daughter ion.
The LOD determined in this way was 1.0 mg/kg for AA I and
1.6 mg/kg for AA II. The LOQwas defined as twice the LOD
and was 2.0 mg/kg for AA I and 3.2 mg/kg for AA II. Two
calibration curves were used, both of which were linear with
correlation coefficients of at least 0.97. The linearity for the
low-level AA ranges was determined between 86 and
430 ng/ml for AA I and between 108 and 540 ng/ml for
AA II. The range of application for preparations containing
high levels of AAs was determined as 430–6,450 ng/ml for
AA I and as 540–8,100 ng/ml for AA II. The calibration
curves for the high concentration range were established by
quadratic regression. Preparations containing even higher
amounts of AAs were diluted with the extraction solution.
The validity of the calibration curve, retention times and
LOD were checked with each series of samples. Quantifica-
tion of both AA I and AA II was based on the first daughter
ions; however, amounts were only quantified when the
relative intensity of the second daughter ion in proportion to
the first daughter ion was within specific limits. For this the
peak surface of the second daughter ion was calculated as a
percentage of the peak surface of the first daughter ion.
For AA I the relative intensity of the second daughter
ion (m/z 341.7) had to be 44.0±11.0% of the first daughter
ion (m/z 298.0). Similarly for AA II the relative intensity of
the second daughter ion (m/z 294.0) had to be 53.5±10.7%
of the first daughter ion (m/z 267.9).
For the recovery studies a blank THP sampled from the
market (labeled as Mu Tong and Clematis armandii and
analytically shown to be free of AA I and AA II) was
spiked at levels between 2 and 11 mg/kg. As Mu Tong
samples were expected to be frequently contaminated, this
blank Mu Tong sample without AAs was considered to be a
relevant model for our research and the recovery studies
were therefore performed on this sample. The recoveries
determined from six replicate measurements under repeat-
ability conditions and in the range 2–11 mg/kg were 87 and
82%, respectively, for AAI and AAII with relative standard
deviations of 3.7 and 3.5%, respectively. The reproducibil-
ity was defined as 2.8 times the standard deviation obtained
from results determined by different operators and at different
times using SCMs. For AA I a SCM, a Xi Xin THP sampled
from the market containing 4.75 mg/kg AA I, was used to
determine the reproducibility, which amounted to
0.94 mg/kg. For AA II a SCM was prepared from a
mixture of a Guan Mu Tong THP sampled from the
market (an Aristolochia sp. with a high level of AA II) and
the blank Mu Tong sample without any AAs which was
used for the recovery studies. This mixture contained
3.76 mg/kg AA II and the reproducibility was 0.47 mg/
kg. Both SCMs were analyzed in each series. These
performance characteristics of the method are in agreement
with results reported by Trujillo et al. [30].
Confusion of herbs in TCM and sampling
of AA-containing THPs
Besides a sensitive analytical method, an effective sampling
protocol needed to be developed for enforcement of the ban
on AAs. Central to this protocol was information on which
Chinese herbs can possibly be replaced by herbs that
Table 4 Mass spectrometry (MS) conditions for the determination of
AA I and AA II
Parameters Conditions
Capillary temperature 250°C
Sheath gas 45%
Aux/sweep 10
Source voltage 5.00 kV
Source current 80.00 μA
Capillary voltage 9.00 V
Tube lens offset 15.00 V
Scan m/z 100.00–400.00
Parent ion AA I m/z 359.0: first daughter ion m/z 298.0;
second daughter ion m/z 341.7
Parent ion AA II m/z 329.1: first daughter ion m/z 267.9;
second daughter ion m/z 294.0
Anal Bioanal Chem (2007) 389:263–275 267
contain AAs. In TCM confusion of herbs occurs frequently
and can result from similarities in appearance, mistakes in
(ancient) textbooks, counterfeits and in many cases ambig-
uous nomenclature [31]. Contamination of THPs with AAs
can often be traced back to confusion over nomenclature.
Common or vernacular names of plants are, as opposed to
binomial botanical names, not very reliable for unambigu-
ous identification of the particular species as, for instance,
the interpretation of common names can even differ
between geographical regions. In TCM several plant
species share a Chinese common name with an Aristolochia
sp. and this common name could be seen as a group name
for the species concerned. When a prefix is added to the
group name the common name refers to only one or two
plant species of the group; in many cases, however, only
the group name is used. The prefix can point at a region
where the plant is grown; for example, the prefix “Chuan”
refers to the Sichuan province [1]. The common name Fang
Ji refers to at least four plant species but in combination
with the prefix “Guang” it is exclusively used for the root
of A. fangchi. There is also the possibility that a herb has
more than one common name, which can lead to confusion
as well. For instance, it was recently reported that
A. mollissima is not only called Xun Gu Feng but Bai
Mao Teng as well. This last common name is also used for
Solanum lyratum, which confusingly has an alternative
name as well, namely, Bai Ying [32]. Substitution of
S. lyratum by A. mollissima can occur when only the
common name Bai Mao Teng is used when the THP is
prescribed, self-medicated, traded, etc. Such a case has been
reported in HongKong recently where a 60-year-oldmanwas
diagnosed with renal failure and urethral cancer after he had
erroneously been using Herba Aristolochiae Mollissimae
instead of the desired Solanum species [31]. The authors
indicated that confusion keeps recurring between the names
Xun Gu Feng, Bai Mao Teng and Bai Ying [31]. Although
A. mollissima is entered in the FDA list, the plant’s common
name is not mentioned nor is S. lyratum [24]. Information of
this nature might prove valuable when sampling THPs for
AA analysis. Tables 1 and 2 present an extract of our
sampling list defining the most pertinent single-herb THPs
derived from Aristolochia spp. in use in TCM, several plant
species which could be replaced by Aristolochia spp. and a
list of possibly contaminated formulas. This list proved
useful for sampling 190 Chinese THPs on the Dutch market
in the period from November 2002 to June 2006.
Analytical results
The Chinese common names and Latin pharmaceutical
names of all 190 THPs were examined for indications that
AA-containing herbs might be present. We identified 68
THPs as products which could possibly contain AAs and
this subgroup contained all 25 positive samples. The
analytical results of the 68 potentially AA-containing THPs
are presented in Table 5 grouped by the Chinese common
name. AA I was found in all 25 samples positive for AA,
the AA I level of four THPs was below the LOQ and AA I
contents of the remaining samples ranged between 2 and
1,676 mg/kg. Together with AA I, AA II was detected in 13
samples, with the AA II content of one sample below the LOQ
and that of the other samples between 4 and 444 mg/kg.When
THPs contained more than the relevant LOQ action was taken
to remove the products from the market.
In three of five samples of single-herb THPs (Guan Mu
Tong (2x), QingMuXian, Guang Fang Ji and Tian Xian Teng)
labeled with names exclusively referring to Aristolochia
species, significant amounts of AA I were found ranging
between 74 and more than 1,000 mg/kg, implying that these
samples indeed contained Aristolochia spp. The remaining
two of these Aristolochia samples surprisingly contained no
detectable levels of AAs. The identity of the samples was
generally not authenticated however. In 11 of 12 samples of
THPs with herbs from the genus Asarum, which also belongs
to the Aristolochiaceae and in which AAs can be expected,
low levels of AAs were detected. The remaining 11 positive
samples were THPs that contained herbs which can be
substituted by Aristolochia spp. and belonged to the Fang Ji
and Mu Tong groups of Table 5. Of these, four products
were incorrectly labeled with names that identified the herbs
as AA-free counterparts of Aristolochia species. This shows
that the problem in TCM of substitution of innocuous herbs
with Aristolochia spp. is not yet resolved. The problem of
substitution of Chinese herbs with toxic counterparts is not
limited to Aristolochia spp. In 2001 the Dutch Health
authorities, including the VWA, were faced with more than
60 poisonings with symptoms including epileptic seizures
owing to consumption of a herbal tea where the spice
Chinese star anise (Illicium verum) was replaced by an
unidentified Illicium sp. imported from China and which was
shown to contain the neurotoxin anisatin [33].
We found no AAs in THPs which to our knowledge
were not likely to be contaminated with AAs and could
therefore be considered as randomly sampled. These THPs
are presented in Table 6. Though AAs were absent, some of
these products could pose a health risk to the user because
they may contain other natural toxins. For example, we
sampled two THPs labeled as Chuan Wu and Radix Aconiti
Carmichaeli, which is the root of Aconitum carmichaeli.
This plant and the related A. kusnezoffii (Cao Wu) are used
in TCM for the treatment of musculoskeletal disorders and
contain the potent neurotoxin and cardiotoxin aconitine. In
Hong Kong cases of herb-induced aconitine poisonings are
treated almost every year [34]. Also several herbs were
sampled that are known to contain pyrrolizidine alkaloids
(PAs), which are mutagenic and carcinogenic hepatotox-
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icants [12]. The pyrrolizidine alkaloid containing herbs are Zi
Cao (Arnebia euchroma and Lithospermum erythrorhizon),
Kuang DongHua (Tussilago farfara) and Pei Lan (Eupatorium
fortunei) [35]. Altogether, based on our results it can be
concluded that especially single herb THPs under the
Chinese common names of Mu Tong, Fang Ji, Tian Xian
Table 5 LC-MS detection of AAs in Chinese THPs potentially containing AAs sampled on the Dutch market
Chinese common name Latin pharmaceutical name N AA (mg/kg) in positive samples
Group Specific names,
when labeled
When labeled Without
AA
With
AA
AA I Mean
AA I
AA II Mean
AA II
Mu Tong Guang Mu Tong – 2 919;
>1,000
82;
> 100
Guang Mu tong Caulis Clematidis Armandii 1 ND ND
Mu Tong – 1 1,453 303
Mu Tong (2x)/– (3x) Caulis Clematidis Armandii—
Akebiae/Caulis Clemat(id)is
Armandii (4x)
5 ND ND
Mu Tong Caulis Akebiae 1 1,281 394
Chung Mu Tong/
Chuan Mu Tong(2x)/
Chuang Mu Tong
Caulis Akebiae(4x) 1 3 19;
1,113;
1,676
936 4;
190;
444
212
Mu tong (in
formula)
Lon Dan Xie Gan (Pian)/
Long Dan Xie Gan Tang
–/Gentiana form 4 3 41;
49;
59
50 11;
9; 14
11
– Quell Fire 1 ND ND
Xao Feng San Tangkuei & Arctium Formula 1 ND ND
Dao Chi San Rehm. Clematis Armandi Form. 1 ND ND
Xiao Feng San Tangkuei & Arctium Formula 1 ND ND
Mu Xiang Qing Mu Xiang Radix Aristolochiae, “Duitse
pijp”
1 ND ND
Mu Xian – 1 ND ND
Mu Xiang Vladimiria 1 ND ND
Guang Mu Xiang – 1 ND ND
Tian Xian
Teng
Tian Xian Teng Caulis Aristolochiae 1 74 33
Fang Ji Niu Ru Shi Cocculi Sarm. Rad. 1 <LOQ ND
Guang Fang Ji – 1 ND ND
Fang Ji – 1 ND ND
Fanji Sclerotium Poriae Cocos 1 12 <LOQ
Fang Ji/– Radix Stefaniae Tetrandiae (2x) 2 ND ND
Fang Ji (in
formula)
Fang Ji Qi Tang Wutian & Astrag. Comb 1 ND ND
Mu Fang Ji Tang Gypsum, Cinn & Ginseng
Comb
1 524 21
Xi Xin Xi Xin (Bei) (1x)/Xi Xin Herba Asari (North) (2x)/Herba
Asari/Herba Asari Cum Radice
1 10 <LOQ–
31
9 ND
Xi Xin (in
formula)
Dang Gui Si Ni Tang Tangkuei & Jujube 1 <LOQ ND
Wei Ling Xian Wei Ling Xian Clematis/ Radix Clematidis/
Radix Clematidis Chinensis
10 ND ND
–/– Clematidis/Radix Clematidis 5 ND ND
Wei Ling Xian (in
formula)
Shu Jing Huo Xue Tang Clematis & Peony Comb 1 ND ND
Ba Yue Zha Ba Yue Zha Fructus Akebiae 2 ND ND
The combinations of Chinese common names and Latin pharmaceutical names were copied from the label or provided by the vendor. No
translations of Chinese names into Latin pharmaceutical names were added by the authors. Dashes indicate that a name was not present on the
label or that the vendor could not specify the name. Chinese common names with small differences which were deemed alternative names were
grouped
LOQ limit of quantification, ND not detected
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Table 6 Randomly sampled Chinese THPs negative for AAs as determined with LC-MS
Chinese common name, as labeled Latin pharmaceutical name, as labeled
Ba Zhen Wan –
Ba Zheng Ke Li Octo Form granules
Bai Hua She She Cao Herba Hedyoti Diffusae
Bai Qui Feng –
Bao He Wan –
Bi Xie Rhizoma Dioscorea Hypoglaucae
Bian Dou Semen Lablab Album
Bing Lang –
Cang Zhu Rhizoma Atracttylodi
Che Qian Cao (2x) Plantago Asiatica/Herba Plantagaginis
Chuan Wu/Chuang Mu/– R. A. Carmichaeli (2x)/Aconit Carmichaeli Preparata
Da Huang (2x) –
Dang Gui Chinese Angelica
Dao Chi Pian Scarlet Form
Ding Chuan Wan –
Du Zhong Bu Yao Granules –
Fan Xie Ye Folium Sennae
Fang Feng Radix Sapashnikovae S
Fu Ling (3x)/– (2x) Sclerotium Poriae Cocos (5x)
Fu Ping –
Gui Fu Di Huang Wan –
Guo Teng Rumulus Unicare Cum Uncis
He Shou Wu (2x)/– Radix Polygoni Multiflori (3x)
Hong Hua Flos Carthami Tinctorii
Huai Hua Flos Sophorae
Huang Jing Rhizoma Polygonati, Polygonum officinale
Huang Lian Tang Granules –
Huo Xiang Zheng Qi Wan –
Je Yiao Teng Caulis Polygoni Multiflori
Jian Pi Wan –
Jinkuishenqiwan –
Ku Shen Pian –
Kuan Dong Hua (3x)/ – (2x) / Dong Hua Flos Tussilagi Farfarae (6x)
Lei Gong Teng Herba Polygoni Perfoliali
Li Zhong Ke Li Midrif Form granules
Ma Chi Xian Herba Portulacae
Mai Wei Di Huang Wan –
Mi Niao Ning Ke Li –
Mi niao ning ke li –
Qing Fei Ping Chuan Tang Granules –
Qing Qi Hua Tan Pian –
Quang Huo Rhizoma Radix Notop Tergii
Ren Shen Ye Folium Ginseng
Sang Ju Yin Ke Li Chrysanth Form
Sang Zhi –
Shenzhi Jiaonang –
Shu Gan Wan –
Shugawan –
Su Mu Lignum Sappan
Te Xiao Yao Tong Ling –
Tiang Huang –
Wu ji bai fe –
Wu ji bai feng wan –
Wu Yao R. L. Strychnifoliae
Xi Zhi Ren Black Cardamom
Xia Sang Ju Chong Ji –
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Teng and Xi Xin could be contaminated with AAs. Besides
single-herb THPs, certain multi-ingredient THPs can be at
risk of adulteration as well (Table 5).
In the following paragraphs we will expand on the
possible reasons for contamination of these particular THPs
with AAs.
Mu Tong
We found AAs in seven out of 14 single-herb THPs with
the pharmaceutical names Caulis Akebia or Caulis Clematis
armandii or Mu Tong with or without the prefixes “Guan”
or “Chuan.” The common Chinese name Guan Mu Tong
exclusively refers to the stem of A. manshuriensis [23] and
two samples exclusively labeled as Guang Mu Tong [sic]
contained an AA I level of 919 and 1,000 mg/kg or higher
and the AA II contents were 82 and more than 100 mg/kg,
respectively. Hashimoto et al. [3] reported AA I contents of
A. manshuriensis (Kan-mokutsu in Japanese) ranging
between 0.169 and 0.882%, which is more than 1.5–8.8
times higher than the levels we found. Trujillo et al. [30]
reported an AA content of 2,830 mg/kg in a sample of A.
manshuriensis stem. In our study another sample, verbally
indicated to be “Guang Mu Tong” [sic] but labeled as
Caulis Clematidis Armandii contained no AAs. The stem of
C. armandii is called Chuan Mu Tong, however. We
therefore conclude that the prefix “Guang” was mistaken
for “Chuan,” which would explain the absence of AAs. A
further five samples labeled as Caulis Clematidis Armandii
with or without Mu Tong did, as expected, not contain
AAs. Of the positive samples, three were labeled as a
Chuan Mu Tong and Caulis Akebia (stem of A. quinata or
A. trifoliata), which to our knowledge is not a common
combination. The common Chinese name of Caulis Akebia
is Bai Mu Tong and not Chuan Mu Tong, which refers to
the stem of C. armandii and C. montana [1, 23].
Table 6 (continued)
Chinese common name, as labeled Latin pharmaceutical name, as labeled
Xiang Yuan Flos C. Mediae
Xiao Feng Ke Li Lay Wind Form
Xiao Ji –
Xiao Yao San Tangkuei & Bupleurum Formula
Ya Dan Zi Fructus Brucae Jav
Yan Fu Mu –
Yang Xue Sheng Fa Jiao Nang –
Ye Jiae Tang –
Yin Chen Herba Artemisiae Scopariae (2x)
Yu Mi Xu Stigma Maydis
Yu Zhu (2x)/– Rhizoma Polygonati/ Polygonati Odorati (2x)
Ze Lan/– Herba Lycopi (2x)
Zi Cao Radix Arnebiae S. Lithosspermi (2x)
Zi Cao (2x) Radix Arnebiae (2x)
Zi Hua Di Ding Herba Violae
Zuo Gui Wan –
– Aconite Ginseng & Ginger Combination
– Artemisia Scoparia
– Astragalus extract tablets
– Beautifying and slimming tea
– Bupleurum & Dragon Bone Combination
– Flos Chrysanthemi (3x)
– Herba Artemisiae Annuae
– Herba Eupatorii Fortunei (2x)
– Herba Lobeliae Chinensis Cum Radice (2x)
– Plantaginia Semen extract
– Radix Phytolaccae
– Radix Pulsatilae Chinenses
– Radix Rubiae
– Rehmannia Eight Formulas
– Rhizoma Dryopteria Crassihizomae (2x)
– Taraxaci Herbs
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Furthermore, two THPs labeled as Mu Tong, one of which
also labeled as Caulis Akebiae, contained high levels of
both AA I and AA II. These findings strongly underline the
fact that the nomenclature of THPs cannot to be relied upon
in some cases. Also the fact that AAs were found in half of
the Mu Tong samples indicates that this group of THPs
needs constant monitoring. Bensky and Gamble [1] noted
that in premodern China Akebia was used as Mu Tong but
that at present A. manshuriensis is used most often.
The formula Long Dan Xie Gan Wan is included in the
FDA list of potential AA-containing herbs and formulas
[24]. The suffix “Wan” in the formula name refers to pill in
Pin Yin [1]. The formula Long Dan Xie Gan Tang is
reported to contain ten ingredients among which is Caulis
Mu Tong [25], for which either A. manshuriensis or the
known Akebia spp. and Clematis spp. can be used [1]. In
our study we sampled Long Dan Xie Gan and related
products with the suffixes “Pian” (tablet) and “Tang”
(decoction) [1, 25] and found 41–59 mg/kg AA I in three
of eight related samples. Health authorities such as Health
Canada and the MHRA in the UK issued warnings against
the use of this product in 2002 and 2003 [15, 16].
Alternative names are “Quell fire” and “Lung Tan Xie
Gan pills” [36]. Quell fire tablets were taken of the market
in 2000 and reformulated as requested by the FDA after the
detection of AAs [37]. We found no AAs in one sample of
Quell fire which had a different lot number and expiry date
than the earlier recalled lots [37]. A case of end-stage renal
failure and recurrent carcinomas in the bladder due to the 5-
year use of Longdan Xieganwan manufactured in China
was reported in the UK [38]. The formulas Dao Chi San
and Xiao Feng San were each sampled once and were
found to be negative for AAs in our study. Both formulas
contain Caulis Mu Tong but some of the classical sources
describe Xiao Feng San without this herb however [25].
Xiao Feng San has been found to contain AAs in Australia
[18]. The FDA included the formula Dao Chi Wan in the
listing of THPs suspected to contain AAs [24]. This
formula has probably the same composition as Dao Chi San
except that the latter is a powder (San) instead of a pill (Wan)
[25]. It is prudent to include the formulas Long Dan Xie
Gan, Dao Chi San and Xiao Feng San in a sampling protocol
because of the possible inclusion of A. manshuriensis.
Mu Xiang and Tian Xian Teng
No AAs were detected in four related Mu Xiang samples.
This common name can refer to the roots of A. debilis,
Aucklandii lappa, Saussurea lappa, Inula helenium,
I. racemosa and Vladimiria souliei [23]. Qing Mu Xian
exclusively refers to the root of A. debilis (Table 1) but a
sample of this THP contained contrary to expectations no
AAs. Although our samples of Mu Xian, Guang Mu Xian
(the root of S. lappa) and Vladimiria (Chuan Mu Xian is the
root of V. souliei [1]) could potentially be substituted by
A. debilis we did not detect AAs. This is in agreement with
information from the European Agency for the Evaluation of
Medicinal Products [23]. More research is needed however to
evaluate the likelihood of this particular substitution. Another
single-herb THP originating from an Aristolochia sp. is Tian
Xian Teng, which according to the Chinese Pharmacopoeia
is Herba Aristolochiae derived from A. contorta and A. debilis.
A sample of this THP was found to contain 74 mg/kg of
AA I and 33 mg/kg of AA II. Although Tian Xian Teng
was sampled once and might not be very common on the
market it should be included in sampling protocols.
Fang Ji
In TCM the common name Fang Ji generally refers to
several different herbs, namely, Cocculus trilobus, Cocculus
orbiculatus, S. tetrandra and A. fangchi. Guang Fang Ji
refers exclusively to A. fangchi and is the only of these
species to contain AAs [1, 23]. We sampled one THP
verbally indicated as Guang Fang Ji which contained no
AA however. A low concentration of AA was detected in a
sample labeled as Fanji and Sclerotium Poriae Cocos. In a
THP called Niu Ru Shiu, unknown to us, but also labeled
as Cocculi Sarm. Rad. traces of AA I were detected.
Obviously “Rad.” stands for “Radix” and in the FDA list
the herbs Cocculus sarmentosus and C. trilobus are
included as alternative names for C. orbiculatus [24]. The
root of C. orbiculatus as well as that of C. trilobus are
called Mu Fang Ji in several sources [1, 39] and might
therefore be substituted with Guang Fang Ji (A. fangchi)
(Table 1) [24]. We found a relatively high AA I
concentration of 523 mg/kg and 21 mg/kg of AA II in the
multi-ingredient THP Mu Fang Ji Tang, which contains
Radix Cocculi Trilobi (Mu Fang Ji) or Radix Stephania
tetrandra (Han Fang Ji) according to some sources [40, 41]
or Radix A. fangchi according to another source [42]. We
found no AAs in three single-herb THP samples labeled as
Radix Stephania tetrandra and/or Fang Ji. This does not
indicate however that Fang Ji requires less attention. An
AA-contaminated THP labeled as Stephania tetrandra was
the cause of the Belgian AAN incident [20–22]. In a Swiss
survey of AA I in commercial samples of slimming regimens
consisting of Chinese plant mixtures four out of 42 tested
positive. AA I was found in a sample Han Fang Ji declared to
be S. tetrandra radix and traces were found in Han Fang Ji
derived from Sinomenium acutum [28]. Both species are
listed in the FDA list [24]. Another multi-ingredient THP
analyzed by the Swiss researchers called Fang Ji Huang Qi
Tang contained traces of AA I but a second sample did not
[28]. We could not detect AAs either in Fang Ji Qi Tang,
which could be a related formula. More attention should be
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focused on multi-ingredient THPs and the lists of these THPs
potentially containing herbs with AAs should be expanded.
Xi Xin
We found low levels of AA I ranging between the LOQ and
31 mg/kg in ten out of 11 samples labeled as Xi Xin, Xi Xin
(Bei) and Herba Asarum or Herba Asarum (North), Herba
Asarum cum Radice samples. No AA II was found. In the
multi-ingredient THP Dang Gui Si Ni Tang we found a small
amount of AA I below the LOQ. This formula contains Xi Xin
(Table 2) [25]. Xi Xin refers to Asarum sieboldii; the genus
Asarum belongs to the Aristolochiaceae and could be
expected to contain AAs. Hashimoto et al. [3] analyzed the
Chinese Asarum spp. A. heterotropoides, A. sieboldii,
A. splendens and A. himalaicum and A. forbesii and found
only traces of AA I in A. splendens and A. himalaicum.
Schaneberg et al. [4] found up to 370 mg/kg AA I but no
AA II in the North American Asarum species A. canadense.
Although the AA levels found in this study are low, batches
of THPs containing Xi Xin should be routinely screened for
AAs before they are brought on the market.
Wei Ling Xian and Ba Yue Zha: likelihood of substitution
by Aristolochia spp.
In the FDA list Wei Ling Xian or the root of Clematis
chinensis is included as a THP which may be adulterated
with AA [24]. The Latin pharmaceutical name is Radix
Clematidis and also refers to the roots of C. hexapetala and
C. uncinata. Substitution of the roots of these herbs by, or
contamination with, the stem of C. armandii or C. montana
(Caulis Clematidis armandii or Chuan Mu Tong), which in
turn can be replaced by the stem of A. manshuriensis (Guan
Mu Tong), seems not likely because these THPs differ in
appearance and moreover the roots of these last Clematis
spp. are not reported to be in use for Wei Ling Xian [1, 43],
which decreases the likelihood of this particular substitution
as well. Another hypothetical option is confusion between
Wei Ling Xian and Qing Mu Xian (the root of A. debilis) but
we found no reports of this substitution. We analyzed ten
samples of Wei Ling Xian/Radix Clematidis (Chinensis), five
samples of Radix Clematidis and a formula containing this
herb [25] but no AAs were found. Our results might indicate
that Radix Clematidis or Wei Ling Xian is not likely to be
replaced by Aristolochia spp. Nevertheless the FDA reported
in 2001 the contamination of a C. chinensis extract with AAs
[44]. More research into this substitution is therefore warranted.
Another herb where substitution by Aristolochia spp.
seems unlikely is Fructus Akebiae or Ba Yue Zha. According
to Bensky and Gamble [1] both names refer to the fruit of
Akebia quinata and A. trifoliata. The fruit of these plants has
also been reported to be referred to as Yu Zhi Zhi in the
Pharmacopoeia of the People's Republic of China and is
entered as such in the FDA list [24, 45]. We found no AAs
in two samples labeled as Fructus Akebiae and Ba Yue Zha.
As the common Chinese name of Fructus Akebiae bears no
resemblance to a common name of any Aristolochia sp.,
confusion would not seem likely. This has to be supported by
additional results, however, before this specific THP may be
considered for removal from the list of suspected materials. It
might be possible that the fruits of A. debilis or A. contorta
(Ma Dou Ling) and Fructus Akebiae are used interchangeably
but we are not aware of reports of such a substitution.
Exposure data
The batches of S. tetrandra powder which were replaced by
Aristolochia spp. in the Belgian AAN incident were
reported to contain AA levels up to 1.56 g/kg with a mean
of 0.65 g/kg [20]. Interestingly only in two of the 12 batches
investigated was tetrandrine, the characteristic alkaloid of
S. tetrandra, found and in one of these in combination with
AAs. This would indicate that the rest of the batches
consisted of 100% Aristolochia spp. replacing S. tetrandra
[20]. It was estimated that the cumulative consumption of
more than 200 g of these powders raised the risk of
urothelial carcinoma [21]. This corresponds to a cumulative
chronic intake of 130 mg of AAs when using the mean AA
content reported by Vanhaelen et al. [20]. We sampled a
THP labeled as Chuan Mu Tong and C. Akebia on the
Dutch market with an AA content of 2.1 g/kg consisting of
a natural mixture of 1.7 g/kg of AA I and 0.44 g/kg of AA
II (Table 5). In a worst-case scenario 62 g of this THP with
the highest AA content would supply more than 130 mg of
AAs, which, considering the Belgian data, could signifi-
cantly raise the risk for cancer. According to Bensky and
Gamble [1] the recommended dose of Mu Tong is 3–9 g,
probably per day. The authors warn against overdose with
reference to a case of acute renal failure following a dose of
60 g. No limitation in the duration of use is given. When in
our worst-case scenario the preparation with the highest AA
content would be used following the highest dosing regimen,
exposure to more than 130 mg of AAs would be achieved in
7 days assuming that all AA is released from the matrix. In the
Belgian cases of urothelial carcinoma the mean exposure
duration was 15 months and generally end-stage renal failure
occurred 3–85 months after cessation of the herbal regimen
[21]. In Belgium the Fang Ji was consumed as a powder,
which might have increased the exposure to AAs. In China,
however, Chinese THPs are mostly used as decoctions,
which might reduce the toxicity of Aristolochia spp.
However, in Chinese literature two cases of acute renal
failure after consumption of a decoction made of 70 and
175 g of Mu Tong, probably Guan Mu Tong, and four deaths
of renal failure after consumption of decoctions of 50–120 g
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of Mu Tong were reported [46]. In the UK two cases were
reported of end-stage renal failure following the use of Mu
Tong containing AA I and AA II. Mu Tong was consumed
by one patient as a tea for 6 years and the other patient used
a preparation for 2 years in a undisclosed way [47].
Conclusion
Our finding that AAs were detected in 25 of 68 THP
samples which could include AA-containing herbs indicates
that several years after the ban in the Netherlands the risk of
inadvertent exposure to AAs remains significant for those
who use these particular THPs. In 1999 the MCA, now the
MHRA, found AAs in 40% of the samples with Fang Ji and
Mu Tong on the UK market [23]. Although the number of
samples is relatively small, we found a similar percentage
of samples containing AAs, namely, 37% of the suspected
samples, which indicates that the situation has not im-
proved since. In the UK the use of Mu Tong, Fang Ji, Ma
Dou Ling or Qing Mu Xiang has been prohibited since
2001. Amongst these are also species such as S. tetrandra,
Clematis spp. and Akebia spp. which do not belong to the
Aristolochiaceae and in themselves do not contain AAs [15].
The Dutch Commodities Act “Herbal preparations” used to
prohibit the sale of Magnolia officinalis and S. tetrandra as
well. After a reevaluation of the literature it was
concluded that these herbs in themselves pose little risk
and subsequently the prohibition of these herbs was
discontinued but it was recognized that a risk of
substitution of S. tetrandra by A. fangchi remained [48].
Internationally the problem of AA-contaminated THPs
still requires attention several years after measures by
regulatory authorities in countries such as Great Britain,
New Zeeland, Canada and Australia and the publicity
generated by this [14–18]. The Belgian AAN tragedy
clearly illustrates that contamination of THPs with AAs
can have very serious consequences. Continued enforce-
ment of the ban of AAs in the Netherlands will show if the
problem of AA contamination of Chinese THPs is
addressed more actively in the field of trade and if stricter
regulatory measures are warranted. When identified, con-
taminated products will be removed from the Dutch market.
The VWA will also in collaboration with customs direct its
enforcement at the import of herbal material in order to
prevent AA-containing THPs from entering the market.
More research into possible contamination of THPs will
help to safeguard the quality of Chinese THPs. As
contamination is unnecessary TCM practitioners, manufac-
turers, vendors and importers of Chinese THPs should
structurally direct efforts to the avoidance of AAs in THPs
known to have the potential for contamination with AAs.
Certification of THPs might aid to prevent the import of
AA-contaminated products but such a system needs close
monitoring. It can be concluded that testing of the imported
herbs for AA contamination is still essential.
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